Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash

Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) will see its price axed by 23.8% in April as it faces a series of price reduction rules including a new post-launch foreign price adjustment and a cut under an ongoing pilot program for...read more